Eiger BioPharmaceuticals Gross Profit

Eiger BioPharmaceuticals (EIGR) currently reports a gross profit of $15M as of December 2023. That compares with $12M in the prior-year period — up 29.9% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Eiger BioPharmaceuticals's gross profit history and peer comparisons.

Eiger BioPharmaceuticals's gross profit increased from $12M to $15M — a 29.9% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eiger BioPharmaceuticals's gross profit of $15M is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eiger BioPharmaceuticals reported $15M in gross profit as of December 2023. That compares with $12M in the prior-year period — up 29.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGR for alerts when major investors trade the stock.